National Evaluation System for health Technology Coordinating Center Publishes Frameworks for Real-World Evidence Studies of Medical Devices

Data Quality and Methods Frameworks focus on ensuring use of high-quality data and methodological considerations in medical device evaluations

ARLINGTON, Va.–(BUSINESS WIRE)–#RWE–The National Evaluation System for health Technology Coordinating Center (NESTcc), an initiative of the Medical Device Innovation Consortium (MDIC), today announced the publication of the NESTcc Data Quality Framework and the NESTcc Methods Framework. Developed by subcommittees of experts from health systems, academia, industry, and the U.S. Food and Drug Administration (FDA), the frameworks provide guiding principles for medical device ecosystem stakeholders to ensure data quality and research methodologies in real-world evidence (RWE) studies.

“The publication of the Data Quality and Methods Frameworks marks a key milestone for NESTcc and reflects the commitment of our team and subcommittees to transform clinical data into high-quality evidence,” said Robbert Zusterzeel, MD, PhD, MPH, director of the NESTcc Data Network at MDIC. “We’re excited to share this important work to help inform clinical and regulatory decision-making and support the health outcomes of people using medical devices.”

Developed from draft versions circulated for public comment last year, these frameworks will evolve in future iterations to incorporate additional data sources for data quality assessment, real-world evidence examples, and further methodology best practices. Both frameworks build upon existing bodies of work and leverage NESTcc subcommittee members’ experience from similar initiatives, including PCORnet, FDA’s Sentinel Initiative, and MDEpiNet.

The Data Quality Framework focuses primarily on the use of EHR data in the clinical care setting, and considers topics including data governance, characteristics, capture and transformation, as well as curation of data. Within the framework, the NESTcc Data Quality Maturity Model addresses the varying stages of an organization’s capacity to support these domains, which allows collaborators to indicate progress toward achieving optimal data quality.

“The Data Quality Framework serves as a guide for organizations that wish to collaborate with NESTcc to ensure the quality of their data related to medical devices,” said Lesley Curtis, PhD, chair and professor of the Department of Population Health Sciences at Duke University School of Medicine and interim executive director at Duke Clinical Research Institute. “The overarching goal of the framework is to enable the effective capture and use of device-related clinical information, which will ultimately, and most importantly, enable better care for patients.”

The Methods Framework is applicable to many different data sources and defines the key components of a study protocol for the evaluation of medical devices. The document promotes overall study design, outlining principles to follow and evidentiary requirements for core elements including disease and device information, target population and patient selection, study outcomes and procedures, sample size, and monitoring and statistical analysis plans.

“The Methods Framework outlines constructs and the importance of the pre-specification of a study protocol to support the rigorous design and execution of RWD research,” said Sharon-Lise Normand, PhD, S. James Adelstein Professor of Health Care Policy for the Department of Health Care Policy at Harvard Medical School, and professor for the Department of Biostatistics at Harvard T.H. Chan School of Public Health. “These design practices for medical device evaluation aim to illuminate the path towards advances in safety, effectiveness, innovation, and transparency.”

The NESTcc Data Quality and Methods Frameworks are accessible in the MDIC Resource Library and on the NESTcc Data Quality and Methods webpage.

About the National Evaluation System for health Technology Coordinating Center

In 2016, the U.S. Food and Drug Administration (FDA) awarded the Medical Device Innovation Consortium (MDIC) $3 million in seed funding to establish the National Evaluation System for health Technology Coordinating Center (NESTcc). The Coordinating Center seeks to support the sustainable generation and use of timely, reliable, and cost-effective Real-World Evidence (RWE) throughout the medical device lifecycle, using Real-World Data (RWD) that meets robust methodological standards and is generated in the course of clinical care and everyday life by patients, providers, or payers, and for the purpose of enhancing regulatory and clinical decision-making. For more information, visit http://www.nestcc.org.

About the Medical Device Innovation Consortium

Founded in 2012, the Medical Device Innovation Consortium (MDIC) is the first public-private partnership created with the sole objective of advancing medical device regulatory science throughout the total product life cycle. MDIC’s mission is to promote public health through science and technology and to enhance trust and confidence among stakeholders. MDIC works in the pre-competitive space to facilitate development of methods, tools, and approaches that enhance understanding and improve evaluation of product safety, quality, and effectiveness. Its initiatives improve product safety and patient access to cutting-edge medical technology while reducing cost and time to market. For more information, visit http://www.mdic.org.

Funding for NESTcc was made possible, in part, by the Food and Drug Administration through grant (1 U01 FD 006292-01). Views expressed in written materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does any mention of trade names, commercial practices, or organization imply endorsement by the United States Government.

Contacts

Sean McNabb
smcnabb@mdic.org
+1 202.688.1337

Staff

Recent Posts

For Pride Month, Mental Health Professionals Offer Parenting Help

Parenting is a hard job under the best of circumstances. It can be especially confusing…

3 hours ago

Curiteva Announces the Beginning of the Commercial Launch of the Inspire(R) Posterior Interbody Solutions

HUNTSVILLE, AL / ACCESSWIRE / June 19, 2024 / Curiteva, Inc., a leading technology and…

3 hours ago

Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically

TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the…

3 hours ago

Sharecare announces inducement grants under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, June 19, 2024 (GLOBE NEWSWIRE) -- Sharecare (NASDAQ: SHCR), the digital health company that…

3 hours ago

Data From Lexicon’s RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Clinical trial of LX9211, an investigational non-opioid investigational therapy, demonstrated clinically significant benefits for people…

3 hours ago

Calibre Scientific Acquires DCS, a German Provider of Antibodies, Reagents and Equipment Used in Immunohistochemistry

LOS ANGELES, June 19, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the…

3 hours ago